YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
ARS Pharmaceuticals, Inc. SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergi…
On August 13, ARS Pharmaceuticals (NASDAQ:SPRY) held its second-quarter 2026 earnings call, the first for new President and CEO Donn Casale. He used it to lay out three priorities: sharper commercial targeting for neffy, tighter financial…
Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 4:30 p.m. ET CALL PARTICIPANTS IR representative - Monique Allaire President and CEO - Donn Casale Chief Financial Officer - Kathy Scott Full Conference Call Transcript Operato…
Shares of ARS Pharmaceuticals, Inc. (SPRY) have gained 5.3% over the past four weeks to close the last trading session at $6.38, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts…
ARS Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Realignment and Commercial Execution Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's…
[Wall Street-Street Sign] P_Wei/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell on Friday. Stock index futures were muted on Friday after the S&P 500 closed at a record high in the previ…
This article first appeared on GuruFocus. Total Revenue: $33.7 million in Q2 2026, reflecting a combination of net product, collaboration, and supply revenue. US Net Product Revenue: $26.2 million for the second quarter. Total Operating Ex…
Key Points Interested in ARS Pharmaceuticals, Inc.? Here are five stocks we like better. Neffy gained traction: ARS reported $26.2 million in second-quarter U.S. net product revenue, while total revenue reached $33.7 million. U.S. market s…
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.46 per share a year ago. These figures are adjusted for non-recurring…
ARS Pharmaceuticals, Inc. $26.2 million in U.S. neffy® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5% and 8% share within field-targeted accounts Commercial investment realigned toward target…
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP reminds purchasers of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities of a pending securities class action brought on behalf of investors who acquired shares between Marc…
SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities b…
Cronos Group (CRON) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.1 per share a year ago. These figures are adjusted for non-recurring items. Thi…
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”)…
ARS Pharmaceuticals, Inc. SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from alle…
ARS Pharmaceuticals Inc. (NASDAQ:SPRY) is one of the 10 best stocks under $10 that could triple. On July 8, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) disclosed a CEO transition, and effective July 6, the company's Co-founder and Chief Executi…
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newacti…
(RTTNews) - ARS Pharmaceuticals Inc. (SPRY), a biopharmaceutical company, on Tuesday announced the immediate succession of Chief Executive Officer (CEO) from co-founder Richard Lowenthal to current President Donn Casale. The company stated…
Crinetics Pharmaceuticals, Inc. CRNX shares rallied 98.7% in the last trading session to close at $83.53. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares…
ARS Pharmaceuticals, Inc. Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of Leadership Since Co-Founding the Company Donn Casale, President, Appointed Chief Executive Officer and Director SAN DIEGO,…
Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of Leadership Since Co-Founding the Company Donn Casale, President, Appointed Chief Executive Officer and Director SAN DIEGO, July 07, 2026 (GLOBE NEWSW…
In late June 2026, ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) was removed from both the Russell 2000 Growth-Defensive Index and the Russell 2000 Defensive Index, altering its presence in widely followed small-cap benchmarks. This dual inde…
This article first appeared on GuruFocus. U.S. stock futures edged higher Thursday as Micron (NASDAQ:MU) gave investors exactly what they wanted: a huge AI memory report and stronger guidance. Micron jumped about 17% after its fiscal Q3 re…
ARS Pharmaceuticals stock collapsed Thursday after CVS Caremark declined to add its epinephrine spray, Neffy, to its formulary. Continue Reading
[Sick young man using nasal spray at home on sofa] canart7 * ARS Pharmaceuticals (SPRY [https://seekingalpha.com/symbol/SPRY]) shares plunged 23% in after-hours trading on Wednesday after the company said its neffy nasal spray failed to se…
[Analyzing Business Performance Through Data Analytics] U.S. stock futures edged higher on Thursday, supported by a stellar earnings report from Micron Technology, as markets turned their focus to the release of key May inflation data for…
ARS Pharmaceuticals, Inc. No new commercial formulary additions or coverage decisions issued for neffy® (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusion Total 2026 ca…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. ARS Pharmaceuticals enters this update cycle with no changes to its existing price targets, which keeps the current ana…
ARS Pharmaceuticals, Inc. Drew BreesDrew Brees, former NFL quarterback, husband, father and philanthropist·GlobeNewswire Inc. Former NFL quarterback and 2026 Hall of Fame inductee highlights daily life for people living with severe food al…
Earnings Call Insights: ARS Pharmaceuticals (SPRY) Q1 2026 MANAGEMENT VIEW * “We are off to a strong start in 2026... building momentum across the business,” said (Co-Founder, President, CEO & Director Richard Lowenthal), highlighting prio…
This article first appeared on GuruFocus. Exploring the Latest 13F Filing of Third Point LLC Daniel Loeb (Trades, Portfolio) recently submitted the 13F filing for the first quarter of 2026, providing insights into his investment moves duri…
This article first appeared on GuruFocus. Total Revenue: $22.7 million in Q1 2026. US Net Product Revenue for Neffy: $17.5 million. Collaboration Revenue: $2.5 million from international partners. Supply Revenue: $2.7 million from internat…
Image source: The Motley Fool. DATE Monday, March 9, 2026, at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Richard LowenthalChief Commercial Officer — Eric KarasChief Financial Officer — Kathleen Scott Need a quote from a Motle…
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.1% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Key Points Interested in ARS Pharmaceuticals, Inc.? Here are five stocks we like better. ARS Pharmaceuticals reported $22.7 million in first-quarter 2026 revenue, with U.S. net product revenue for neffy reaching $17.5 million as prescripti…
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.35 per share a year ago. These figures are adjusted for non-recurring…